CACNA1C and ovarian serous adenocarcinoma: By establishing further in vitro, in vivo, and clinical trials using FDA approved NIFE may be repurposed to target CACNA1C for HGSOC.<h4>Novelty and impact</h4>High-grade serous ovarian cancer (HGSOC) remains lethal due to late diagnosis and drug resistance.